Published in Prostaglandins Other Lipid Mediat on December 30, 2015
A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med (2014) 18.12
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Coxibs and cardiovascular disease. N Engl J Med (2004) 4.42
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res (2000) 3.70
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res (2004) 3.33
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 2.72
Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res (2000) 2.67
Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci (1997) 2.55
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
Astrocytes and the regulation of cerebral blood flow. Trends Neurosci (2009) 2.27
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A (2001) 2.16
Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res (1998) 2.13
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol (2005) 2.10
Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke (2008) 2.10
COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol (2007) 1.77
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci (2000) 1.76
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ Res (2001) 1.69
Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke (1996) 1.68
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol (1994) 1.57
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Interventionalist perspective on the new endovascular trials. Stroke (2015) 1.51
Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J (2007) 1.49
Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by epoxygenase inhibitors. Am J Physiol Heart Circ Physiol (2002) 1.45
Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol (2008) 1.40
Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat (2009) 1.35
Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther (2005) 1.31
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A (2010) 1.29
Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase. Nature (1979) 1.29
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 1.29
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Effects of indomethacin upon cerebral hemodynamics of newborn pigs. Pediatr Res (1985) 1.26
Prostaglandin H synthase and vascular function. Circ Res (2001) 1.23
Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos (2003) 1.23
Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des (2008) 1.23
Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol (2009) 1.23
The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest (1999) 1.22
20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol (2008) 1.22
Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett (2008) 1.19
Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab (2008) 1.19
Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol (2000) 1.19
Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol (1999) 1.19
Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke (2006) 1.18
Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab (2006) 1.18
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis (2007) 1.16
Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J Neurosci Res (2007) 1.16
Metabotropic glutamate receptor activation enhances the activities of two types of Ca2+-activated k+ channels in rat hippocampal astrocytes. J Neurosci (2003) 1.15
Dependency of cortical functional hyperemia to forepaw stimulation on epoxygenase and nitric oxide synthase activities in rats. J Cereb Blood Flow Metab (2004) 1.15
Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther (2006) 1.14
Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes (1998) 1.11
Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol (2011) 1.11
Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther (2010) 1.10
20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol Heart Circ Physiol (2002) 1.08
The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke (2005) 1.08
Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol (2008) 1.06
Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. J Clin Invest (2011) 1.06
Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension (2003) 1.05
Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox Res (2008) 1.05
COX-2 and the kidney. J Cardiovasc Pharmacol (2006) 1.05
Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke (2008) 1.04
Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) (2011) 1.04
Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmunol (2007) 1.04
Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res (2007) 0.99
Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol (2009) 0.99
Stroke Neurologist's Perspective on the New Endovascular Trials. Stroke (2015) 0.98
Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced neuroprotection in the mouse model of surgical brain injury. Stroke (2009) 0.98
Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res (2006) 0.97
Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am J Physiol Renal Physiol (2003) 0.97
Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. PLoS One (2013) 0.97
Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev (2011) 0.96
Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res (2013) 0.95
Cytochrome P450 omega-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol (2008) 0.95
Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol (1999) 0.95
Roles of lipid mediators in kidney injury. Semin Nephrol (2007) 0.94
Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev Mol Med (2011) 0.94
Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int (2008) 0.94
Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res (2003) 0.92
Contribution of epoxyeicosatrienoic acids to the hypoxia-induced activation of Ca2+ -activated K+ channel current in cultured rat hippocampal astrocytes. Neuroscience (2006) 0.91
The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol (2010) 0.91
Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol (2013) 0.90
Protective effect of 20-HETE inhibition in a model of oxygen-glucose deprivation in hippocampal slice cultures. Am J Physiol Heart Circ Physiol (2012) 0.88
Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage. Stroke (2011) 0.87
Epoxyeicosatrienoic acid-dependent cerebral vasodilation evoked by metabotropic glutamate receptor activation in vivo. Am J Physiol Heart Circ Physiol (2011) 0.87
Attenuation of neonatal ischemic brain damage using a 20-HETE synthesis inhibitor. J Neurochem (2012) 0.87
Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol (2006) 0.87
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus. J Cereb Blood Flow Metab (2013) 0.86
Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat (2015) 0.85
Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion. Am J Physiol Regul Integr Comp Physiol (2009) 0.84
The effect of indomethacin on the blood flow-metabolism couple in the brain under normal, hypercapnic and hypoxic conditions. Acta Physiol Scand (1979) 0.83
Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke. PLoS One (2014) 0.82